Inheritance and drug response.

By Richard M. Weinshilboum. New England Journal of Medicine, 2003

1,007 citations recorded by the source corpus.

Subfields: Clinical Biochemistry, Oncology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/0c79e77fe67f6eef105ab11d259c7db63972a638

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Clinical Biochemistry

1. Magnus Ingelman-Sundberg
2. Shufeng Zhou
3. William E. Evans
4. Mary V. Relling
5. F. Schoen
6. Shruti B. Patel
7. Karen Mendelson
8. M. Eichelbaum

In Oncology

1. Shufeng Zhou
2. Jun-Ping Liu
3. B. Chowbay
4. M. Eichelbaum
5. William E. Evans
6. Magnus Ingelman-Sundberg
7. Mary V. Relling
8. F. Schoen

In Pharmacology

1. M. Eichelbaum
2. Magnus Ingelman-Sundberg
3. Shufeng Zhou
4. William E. Evans
5. Jun-Ping Liu
6. B. Chowbay
7. Mary V. Relling
8. F. Schoen

Citations in the corpus

• Moving towards individualized medicine with pharmacogenomics (2004, background): “In the decade that followed, genes responsible for many such inherited differences in drug metabolism and disposition were isolated, characterized and linked to differences in drug effect”
• Sedation and analgesia in the mechanically ventilated patient. (2012, background): “and genetic variations, which affect drug response and metabolism, may change how an individual patient responds to a specific medication (18).”
• Pharmacogenomics and individualized drug therapy. (2006, background): “Variants of the ADRB2, ADRB1, and other G-protein coupled receptors (GPCRs) generally encode hypomorphic proteins, not nonfunctional proteins (3, 99).”
• Engineering Complex Tissues (2006, positive): “This issue is conceptually analogous to the emerging area of pharmaco-genomics, 192 which shows that individual patient characteristics (for example, genetic mutations or polymorphisms) have a profound influence on drug metabolism outcome in some patients.”
• Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, background): “…pharmacogenomics is a more global definition and entails the study of the entire spectrum of genes and their contribution to variability in drug efficacy and toxicity using genomewide approaches (Evans and Relling, 1999; McLeod, 2001; McLeod and Evans, 2001; Weinshilboum, 2003; Zhou et al., 2008).”
• Heart Valve Tissue Engineering: Concepts, Approaches, Progress, and Challenges (2006, background): “179 Simply stated, some patients might not appropriately remodel their tissue-engineered valves, and this could lead to failure (Fig.”